——— OR ———
View Without Audio Commentary

SUBMIT A QUESTION

This website uses "cookies" and collects anonymous usage information to better understand our audience and how they interact with our content. We take privacy seriously and do not collect any information that would be deemed identifiable or personal. By accepting the use of cookies you are consenting to the collection of this information for the purpose as described. Accept / Decline

MEDICAL AFFAIRS
VIRTUAL BOOTH

CLICK ANYWHERE TO CONTINUE

CLICK ANYWHERE TO CONTINUE

X

Please fill-out this form to access the material.

* Indicates a Required Field

1First Name*

2Last Name*

3Institution*

4Specialty*

5Email


Please confirm you are not a bot and try again.

By clicking the submit button, you confirm you are a healthcare professional, the above information is accurate, and you are seeking information about FT218, an investigational form of sodium oxybate under review by FDA.

Privacy Policy

X

Submit a Question

* Indicates a Required Field

1First Name*

2Last Name*

3Institution*

4Email

5Phone

6Preferred Method of Contact*

7State*

8Question*

Please confirm you are not a bot and try again.

Privacy Policy

FT218 is an investigational form of once-nightly sodium oxybate (ON-SXB) currently under review at FDA. ON-SXB has not been approved as safe or effective.

Patient Perspectives

Meet the Avadel Team

Ongoing Research

Sodium in Sodium Oxybate:
Is there cause for concern?

PK Studies

About Avadel

Dr. Asim Roy shares his perspective
on the Phase 3 REST-ON Trial

SLEEP 2021 Oral presentation
by Dr. Michael ThorpyEfficacy of ON-SXB for Excessive Daytime Sleepiness
and PROs: Results from the Phase 3 REST-ON Trial

Interactive Poster Session

Interactive Poster Session

How Narcolepsy
Management is Evolving:Expert Panel Discussion